Search Results for: "abbvie vs amgen"

Litigation Update: Answer Filed in AbbVie v. Amgen

Amgen has filed its answer in response to AbbVie’s complaint alleging infringement of 10 patents that allegedly cover Amgen’s recently-approved adalimumab biosimilar, Amjevita (formerly known as ABP501). Amgen asserts that AbbVie’s responses to its aBLA and required disclosures were deficient.  Specifically, Amgen asserts that AbbVie did not provide an adequate…

Read More

Breaking News: AbbVie Files Complaint Against Amgen

AbbVie has filed a complaint against Amgen related to AbbVie’s Humira (adalimumab).  The complaint asserts patent infringement and also seeks a declaratory judgment to compel Amgen to comply with the BPCIA’s notice of commercial marketing provision. Stay tuned to Big Molecule Watch for more details later today.

Read More